Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemopure advisory committee

Executive Summary

FDA's Blood Products Advisory Committee will meet Dec. 14 to review Biopure's experimental blood product Hemopure [hemoglobin glutamer-250(bovine)] for out-of-hospital treatment of hermorrhagic shock, including the Navy's proposed RESUS clinical trial of the oxygen therapeutic. A closed-door meeting of the panel to discuss Hemopure was scheduled last July but was cancelled due to concerns about the need for more public input (1"The Pink Sheet" Sept. 11, 2006, p. 24). The meeting will be held from 8 a.m. to 6 p.m. at the Crown Plaza in Silver Spring, MD...

You may also be interested in...



FDA May Use Panels More Often To Evaluate Emergency Research Protocols

FDA is questioning whether protocols for emergency research conducted without individual informed consent should be subjected to more public input

Anti-Tau For Alzheimer's In The Dock After Semorinemab Fail

Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.

Indivior Reorganizing And Re-Investing In US Commercial Functions

Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel